Business Context and Reporting Period
Company: Biogen Idec Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Overview: Biogen Idec is a global biotechnology company focused on therapeutic areas with high unmet medical needs, including oncology, neurology, immunology, and cardiology. The company's revenue is heavily dependent on two principal products: AVONEX (multiple sclerosis) and RITUXAN (oncology and rheumatoid arthritis), which represented approximately 88% of total revenues in 2007. The company also markets TYSABRI (multiple sclerosis and Crohn's disease) and FUMADERM (psoriasis).
Key Financial Metrics
| Metric | 2007 | 2006 |
|---|---|---|
| Total Revenues | $3,171.6 million | $2,683.0 million |
| Net Income | $638.2 million | $217.5 million |
| Diluted EPS | $1.99 | $0.63 |
| Research & Development Expenses | $925.2 million | $718.4 million |
| Cash, Cash Equivalents & Marketable Securities | $2,115.8 million | $2,314.9 million |
| Total Debt (Notes Payable) | $1,563.0 million | $96.7 million |
| Working Capital | $179.2 million | $1,129.7 million |
Note: The significant increase in debt in 2007 is primarily due to a $1.5 billion short-term term loan facility utilized to fund a tender offer for the repurchase of 56.4 million shares of common stock.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 18.2% to $3.17 billion. This was driven by a 20.0% increase in product revenues (primarily TYSABRI and AVONEX) and a 14.2% increase in revenue from the unconsolidated joint business (RITUXAN).
- Profitability: Net income increased 193% to $638.2 million, largely due to higher revenues and a lower effective tax rate (29.9% in 2007 vs. 56.6% in 2006).
- Expense Increases: R&D expenses rose 28.8% to $925.2 million due to new clinical trials and upfront payments for collaborations (Cardiokine, Neurimmune). SG&A expenses increased 13.3% to $776.1 million, driven by TYSABRI marketing.
- Capital Structure: The company executed a $2.99 billion tender offer in July 2007, funded by cash and a new $1.5 billion term loan. This significantly reduced working capital and increased interest expense.
- Product Portfolio: In December 2007, the company sold U.S. rights to ZEVALIN to Cell Therapeutics, Inc. for $10 million upfront plus milestones.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D and SG&A expenses to increase in 2008 to support clinical trials and the commercialization of TYSABRI and AVONEX. The company anticipates TYSABRI will be available for Crohn's disease patients by the end of Q1 2008.
- Key Risks:
- Product Dependence: Heavy reliance on AVONEX and RITUXAN (88% of revenue).
- TYSABRI Safety: Success depends on market acceptance despite safety warnings regarding Progressive Multifocal Leukoencephalopathy (PML).
- Regulatory & Legal: Ongoing litigation regarding TYSABRI side effects, RITUXAN promotion practices (DOJ investigation), and Medicaid pricing. An arbitration with Genentech regarding the RITUXAN collaboration agreement is ongoing.
- Manufacturing: Significant investment ($300 million) in a new facility in Hillerod, Denmark, with commercial production expected in 2009.
- Activist Shareholders: Icahn Partners nominated three individuals for the Board of Directors in January 2008, proposing an increase in board size.
Investor Verification Checklist
- Verify the status of the arbitration with Genentech regarding the RITUXAN collaboration and potential change-of-control provisions.
- Monitor the outcome of the DOJ investigation into RITUXAN promotion practices and the class-action lawsuit regarding TYSABRI safety disclosures.
- Assess the timeline and regulatory approval status for TYSABRI in Crohn's disease and the commercial launch in Q1 2008.
- Review the company's plan to refinance the $1.5 billion short-term term loan in 2008.
- Track the progress of the Hillerod, Denmark manufacturing facility construction and its impact on future TYSABRI supply.
- Monitor the impact of the Icahn Partners proxy fight on corporate governance and strategic direction.